Skip to main content
. 2023 Mar 30;7:e2200463. doi: 10.1200/PO.22.00463

FIG 1.

FIG 1.

Flowchart of patient selection. chemo-anti–PD-1/PD-L1, combination of chemotherapy plus anti–PD-1/PD-L1 therapy; CTLA-4, cytotoxic T-lymphocyte–associated antigen-4; dMMR, mismatch repair-deficient; MSI, microsatellite instability; MSS, microsatellite stability; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization.